参考文献/References:
[1]Shah SC, Itzkowitz SH. Colorectal cancer in inflammatory bowel disease: Mechanisms and management. Gastroenterology,2022,162(3):715-730.e3。
[2]Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut,2001,48(4):526-535。
[3]Selinger CP, Andrews JM, Titman A, et al. Long-term follow-up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease. Clin Gastroenterol Hepatol,2014,12(4):644-650。
[4]Kader R, Hadjinicolaou AV, Burr NE, et al. Systematic review and meta-analysis: The three-year post-colonoscopy colorectal cancer rate as per the World Endoscopy Organization Methodology. Clin Gastroenterol Hepatol,2024,27:S1542-3565(24)00789-4。
[5]Wheat CL, Clark-Snustad K, Devine B, et al. Worldwide incidence of colorectal cancer, leukemia, and lymphoma in inflammatory bowel disease: An updated systematic review and meta-analysis. Gastroenterol Res Pract,2016,2016:1632439。
[6]Birch RJ, Burr N, Subramanian V, et al. Inflammatory bowel disease-associated colorectal cancer epidemiology and outcomes: An English population-based study.Am J Gastroenterol,2022,117(11):1858-1870。
[7]张琴,万健,吴开春,等.溃疡性结肠炎癌变流行病学调查:一项全国多中心回顾性研究.中华炎性肠病杂志(中英文),2017,1(3):155-159。
[8]Garg SK, Velayos FS, Kisiel JB. Intestinal and nonintestinal cancer risks for patients with Crohn’s disease. Gastroenterol Clin North Am,2017,46(3):515-529。
[9]Shwaartz C, Munger JA, Deliz JR, et al. Fistula-associated anorectal cancer in the setting of Crohn’s disease. Dis Colon Rectum,2016,59(12):1168-1173。
[10]Canavan C, Abrams KR, Mayberry J. Meta-analysis: Colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther,2006,23(8):1097-1104。
[11]De Jong ME, Van Tilburg SB, Nissen LHC, et al. Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with inflammatory bowel disease: A nationwide cohort study. J Crohns Colitis,2019,13(12):1485-1491。
[12]孙振,侯文运.人工智能在结直肠癌诊疗中的应用进展.中国微创外科杂志,2022,22(11):898-902。
[13]Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study. Gastroenterology,1994,107(1):117-120。
[14]Qiu X, Ma J, Wang K, et al. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: A systematic review with meta-analysis. Oncotarget,2017,8(1):1031-1045。
[15]Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis,2017,11(6):649-670。
[16]Rajam?ki K, Taira A, Katainen R, et al. Genetic and epigenetic characteristics of inflammatory bowel disease-associated colorectal cancer. Gastroenterology,2021,161(2):592-607。
[17]Jans D, Cleynen I. The genetics of non-monogenic IBD. Hum Genet,2023,142(5):669-682。
[18]Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol,2014,14(5):329-342。
[19]朱秀丽, 解丽.溃疡性结肠炎异型增生影响因素的回顾性研究.现代消化及介入诊疗,2022,27(2):160-163。
[20]Giri B, Holubar SD, Liska D, et al. Biologic therapy is associated with improved oncologic outcomes in Crohn’s disease-associated colorectal cancer. Dis Colon Rectum,2025,68(2):227-233。
[21]Krugliak CN, Ghosh S, Chastek C, et al. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: Findings from ROTARY. BMC Gastroenterol,2024,24(1):314。
[22]Zhang Y, Jin Y, Wang Y, et al. Insights of expression profile of chemokine family in inflammatory bowel diseases and carcinogenesis. Int J Mol Sci,2024,25(19):10857。
[23]Wijnands AM, Mahmoud R, Lutgens MWMD, et al. Surveillance and management of colorectal dysplasia and cancer in inflammatory bowel disease: Current practice and future perspectives. Eur J Intern Med,2021,93:35-41。
[24]Shah SC, Itzkowitz SH. Management of inflammatory bowel disease-associated dysplasia in the modern era. Gastrointest Endosc Clin N Am,2019,29(3):531-548。
[25]Kasuga K, Yamada M, Shida D, et al. Treatment outcomes of endoscopic submucosal dissection and surgery for colorectal neoplasms in patients with ulcerative colitis. United European Gastroenterol J,2021,9(8):964-972。
[26]Gordon H, Biancone L, Fiorino G, et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis,2023,17(6):827-854。
[27]Barnes EL, Desai A, Hashash JG, et al. The natural history after ileal pouch-anal anastomosis for ulcerative colitis: A population-based cohort study from the United States. Am J Gastroenterol,2024,119(11):2267-2274。
[28]中华医学会外科学分会结直肠外科学组,中国医师协会肛肠医师分会炎症性肠病专业委员会.中国溃疡性结肠炎外科治疗指南.中华炎性肠病杂志,2022,6(1):7-16。
[29]Spinelli A, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: Surgical treatment. J Crohns Colitis,2022,16(2):179-189。
[30]Derderian SC, Phillips R, Acker SN, et al. Pediatric ulcerative colitis: Three- versus two-stage colectomy with ileal pouch-anal anastomosis. Pediatr Surg Int,2020,36(2):171-177。
[31]Bislenghi G, Martin-Perez B, Fieuws S, et al. Increasing experience of modified two-stage transanal ileal pouch-anal anastomosis for therapy refractory ulcerative colitis. What have we learned? A retrospective analysis on 75 consecutive cases at a tertiary referral hospital. Colorectal Dis,2021,23(1):74-83。
[32]Samples J, Evans K, Chaumont N, et al. Variant two-stage ileal pouch-anal anastomosis: An innovative and effective alternative to standard resection in ulcerative colitis. J Am Coll Surg,2017,224(4):557-563。
[33]Barnes EL, Karachalia Sandri A, Herfarth HH, et al. Antibiotic use in the 12 months prior to ileal pouch-anal anastomosis increases the risk for pouchitis. Clin Gastroenterol Hepatol,2024,22(8):1678-1686.e8。
[34]Travis S, Silverberg MS, Danese S, et al. Vedolizumab for the treatment of chronic pouchitis. N Engl J Med,2023,388(13):1191-1200。
[35]Ryan J, Orsi G, Boland MR, et al. Meta-analysis of early bowel resection versus initial medical therapy in patient’s with ileocolonic Crohn’s disease. Int J Colorectal Dis,2020,35(3):501-512。
[36]Agrawal M, Ebert AC, Poulsen G, et al. Early ileocecal resection for Crohn’s disease is associated with improved long-term outcomes compared with anti-tumor necrosis factor therapy: A population-based cohort study. Gastroenterology,2023,165(4):976-985.e3。
[37]Grellier N, Kirchgesner J, Uzzan M, et al. Early ileal resection in Crohn’s disease is not associated with severe long-term outcomes: The ERIC study. Aliment Pharmacol Ther,2024,60(10):1388-1397。
[38]Adamina M, Minozzi S, Warusavitarne J, et al. ECCO guidelines on therapeutics in Crohn’s disease: Surgical treatment. J Crohns Colitis,2024,18(10):1556-1582。
[39]Kono T, Ashida T, Ebisawa Y, et al. A new antimesenteric functional end-to-end handsewn anastomosis: Surgical prevention of anastomotic recurrence in Crohn’s disease. Dis Colon Rectum,2011,54(5):586-592。
[40]Luglio G, Rispo A, Imperatore N, et al. Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s disease: The SuPREMe-CD Study-A randomized clinical trial. Ann Surg,2020,272(2):210-217。
[41]Haanappel AEG, Bellato V, Buskens CJ, et al. Optimising surgical anastomosis in ileocolic resection for Crohn’s disease with respect to recurrence and functionality: Two international parallel randomized controlled trials comparing handsewn (END-to-end or Kono-S) to stapled anastomosis (HAND2END and the End2End STUDIES). BMC Surg,2024,24(1):71。
[42]Murthy SK, Kuenzig ME, Windsor JW, et al. The 2023 impact of inflammatory bowel disease in Canada: Cancer and IBD. J Can Assoc Gastroenterol,2023,6(Suppl 2):S83-S92。
[43]Ording AG, Horváth-puhó E, Erichsen R, et al. Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn’s disease: A nationwide population-based cohort study. Inflamm Bowel Dis,2013,19(4):800-805。
[44]Lu C, Schardey J, Zhang T, et al. Survival outcomes and clinicopathological features in inflammatory bowel disease-associated colorectal cancer: A systematic review and meta-analysis. Ann Surg,2022,276(5):E319-E330。
[45]Ou B, Zhao J, Guan S, et al. Survival of colorectal cancer in patients with or without inflammatory bowel disease: A meta-analysis. Dig Dis Sci,2016,61(3):881-889。
[46]Dugum M, Lin J, Lopez R, et al. Recurrence and survival rates of inflammatory bowel disease-associated colorectal cancer following postoperative chemotherapy: A comparative study. Gastroenterol Rep(Oxf),2017,5(1):57-61。